Duloxetine: A Dual Serotonin‐Norepinephrine Reuptake Inhibitor for Treatment of Major Depressive Disorder

Kirwin, Jennifer L.; Gören, Jessica L.

doi:10.1592/phco.25.3.396.61600

Cited by 43Treatment of Major DepressionPsychological Treatments and DisordersAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Duloxetine: A Dual Serotonin‐Norepinephrine Reuptake Inhibitor for Treatment of Major Depressive Disorder

Kirwin, Jennifer L., Gören, Jessica L.·2005·Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

DOI 10.1592/phco.25.3.396.61600

Open this paper in CoChat — free account

Abstract

The burden of mental illness has been underestimated worldwide. Depression was the fourth leading cause of disease burden in the world in 1990 and is projected to be the second leading cause of disability by 2020. It is a leading cause of morbidity and mortality in the United States, costing billions of dollars annually in direct and indirect medical costs and losses in productivity. Patients with major depressive disorder (MDD) may experience both psychological and medical complaints, including somatic sensations or pain. Some antidepressants have been shown to treat chronic pain syndromes, but despite the variety of antidepressants available in the United States, only 65–70% of patients respond to initial antidepressant treatment. Treatments are limited by delayed onset of antidepressant effects, side effects, partial response, and treatment resistance. Duloxetine, approved by the U.S. Food and Drug Administration for the treatment of MDD, is a reuptake inhibitor at serotonergic and noradrenergic neurons and appears to have low affinity for other neurotransmitter systems. In clinical trials, duloxetine was effective for the treatment of MDD and was well tolerated. Further study is needed to compare its efficacy with that of other antidepressants, to clarify effects on somatic symptoms, and to assess potential adverse cardiovascular and sexual side effects. Duloxetine is also approved for the management of diabetic peripheral neuropathic pain and is under investigation for the treatment of stress urinary incontinence in women.

Integrity signals

Registry

Crossref · 10.1592/phco.25.3.396.61600

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Side effects more specific to serotonin or norepinephrine have become a concern.
“In addition, side effects which are more specific to serotonin or norepinephrine also have become a concern.56”
From Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review (2018) · cites this paper as [6]

A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · see citing works
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States: Results From the National Comorbidity Survey
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · see citing works
One-Month Prevalence of Mental Disorders in the United States: Based on Five Epidemiologic Catchment Area Sites
Regier, D. A. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800350011002 · Cited by 1,737 · see citing works
Neuropsychopharmacology
Bunney, W. E., Hippius, H., Laakmann, G., & Schmauß, M. (1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523 · see citing works
The Economic Burden of Depression in the United States: How Did It Change Between 1990 and 2000?
Greenberg, P. E., Kessler, R. C., Birnbaum, H. G., Leong, S. A., Lowe, S. W., Berglund, P. A., & Corey-Lisle, P. K. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1211 · Cited by 1,280 · see citing works
Economic burden of depression
Greenberg, P. E., Stiglin, L. E., Finkelstein, S. N., & Berndt, E. R. (1994) · PharmacoResources · doi:10.1007/bf03289581 · Cited by 974 · see citing works
Distributed Disturbances in Brain Structure and Function in Schizophrenia
Lewis, D. A. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 971 · see citing works
Modulation of neurotransmitter release by presynaptic autoreceptors
Starke, K., Göthert, M., & Kilbinger, H. J. (1989) · Physiological Reviews · doi:10.1152/physrev.1989.69.3.864 · Cited by 927 · see citing works
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801 · see citing works
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797 · see citing works
The Visual Analog Scale in the Immediate Postoperative Period
DeLoach, L. J., Higgins, M. S., Caplan, A. B., & Stiff, J. L. (1998) · Anesthesia & Analgesia · doi:10.1097/00000539-199801000-00020 · Cited by 727 · see citing works
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis
Smith, D. D., Dempster, C., Glanville, J., Freemantle, N., & Anderson, I. M. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.180.5.396 · Cited by 537 · see citing works
Duloxetine, 60 mg Once Daily, for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384 · see citing works
Managing Depression in Medical Outpatients
Whooley, M. A., & Simon, G. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432607 · Cited by 374 · see citing works
Antidepressants and Anticonvulsants for Diabetic Neuropathy and Postherpetic Neuralgia
Collins, S., Moore, R. A., McQuay, H. J., & Wiffen, P. J. (2000) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(00)00218-9 · Cited by 351 · see citing works
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334 · see citing works
A 40-Year Perspective on the Prevalence of Depression: The Stirling County Study
Murphy, J. M., Laird, N. M., Monson, R. R., Sobol, A. M., & Leighton, A. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.209 · Cited by 318 · see citing works
Duloxetine in the Treatment of Depression: A Double-Blind Placebo-Controlled Comparison With Paroxetine
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314 · see citing works
A Preliminary, Open Study of the Combination of Fluoxetine and Desipramine for Rapid Treatment of Major Depression
Nelson, J. C. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810280019002 · Cited by 294 · see citing works
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression
Detke, M. J., Lu, Y., GOLDSTEIN, D. J., McNamara, R. K., & Demitrack, M. A. (2002) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(02)00060-2 · Cited by 278 · see citing works
SSRIs versus tricyclic antidepressants in depressed inpatients: A meta-analysis of efficacy and tolerability
Anderson, I. M. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:1+ · Cited by 277 · see citing works
Texas Medication Algorithm Project
Gilbert, D. A., Altshuler, K. Z., Rago, W. V., Shon, S. P., Crismon, M. L., Toprac, M. G., & Rush, A. J. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0702 · Cited by 264 · see citing works
The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder
Crismon, M. L., Trivedi, M., Pigott, T. A., Rush, A. J., Hirschfeld, R. M. A., Kahn, D. A., DeBattista, C., Nelson, J. C., Nierenberg, A. A., Sackeim, H. A., et al. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0302 · Cited by 250 · see citing works
Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat.
Chaput, Y., de Montigny, C., & Blier, P. U. (1991) · PubMed · Cited by 249 · see citing works
The Use of Antidepressants in the Treatment of Chronic Pain
Magni, G. (1991) · Drugs · doi:10.2165/00003495-199142050-00002 · Cited by 247 · see citing works
LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake
Wong, D. T., Bymaster, F. P., Mayle, D. A., Reid, L. R., Krushinski, J. H., & Robertson, D. W. (1993) · Neuropsychopharmacology · doi:10.1038/npp.1993.4 · Cited by 222 · see citing works
Fluoxetine Treatment of Patients With Major Depressive Disorder Who Failed Initial Treatment With Sertraline
Thase, M. E., Blomgren, S. L., Birkett, M. A., Apter, J. T., & Tepner, R. G. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0103 · Cited by 204 · see citing works
Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers
Skinner, M., Kuan, H., Pan, A. X., Sathirakul, K., Knadler, M. P., Gonzales, C., Yeo, K. P., Reddy, S. R., Lim, M., Ayan‐Oshodi, M., et al. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.28 · Cited by 195 · see citing works
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study
Nelson, J. C., Mazure, C. M., Jatlow, P. I., Bowers, M. B., & Price, L. H. (2003) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.08.007 · Cited by 190 · see citing works
Venlafaxine and paroxetine in treatment-resistant depression: Double-blind, randomised comparison
Poirier, M.-F., & Boyer, P. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.1.12 · Cited by 185 · see citing works
Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomised controlled trials
Barbui, C., & Hotopf, M. H. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.2.129 · Cited by 182 · see citing works
Venlafaxine and paroxetine in treatment-resistant depression
Gregson, J. R. (1999) · The British Journal of Psychiatry · doi:10.1192/bjp.175.6.591a · Cited by 171 · see citing works
Effects of Duloxetine on Painful Physical Symptoms Associated With Depression
GOLDSTEIN, D. J., Lu, Y., Detke, M. J., Hudson, J. I., Iyengar, S., & Demitrack, M. A. (2004) · Psychosomatics · doi:10.1176/appi.psy.45.1.17 · Cited by 154 · see citing works
Pharmacokinetics and Safety of Duloxetine, a Dual‐Serotonin and Norepinephrine Reuptake Inhibitor
Sharma, A., Goldberg, M. J., & Cerimele, B. J. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022008810 · Cited by 147 · see citing works
Combining Antidepressants for Treatment-Resistant Depression
Lam, R. W. M., Wan, D. D. C., Cohen, N. L., & Kennedy, S. H. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0805 · Cited by 113 · see citing works
Duloxetine in the Long-Term Treatment of Major Depressive Disorder
Raskin, J., GOLDSTEIN, D. J., Mallinckrodt, C. H., & Ferguson, M. B. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1015 · Cited by 111 · see citing works
Assessment of the Serotonin and Norepinephrine Reuptake Blocking Properties of Duloxetine in Healthy Subjects
Turcotte, J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00220-7 · Cited by 110 · see citing works
Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters
Béïque, J.-C., Lavoie, N., de Montigny, C., & Debonnel, G. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00241-6 · Cited by 107 · see citing works
Does Depression Hurt?
Stahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0401 · Cited by 105 · see citing works
α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving Rats
Gobert, A., Rivet, J., Cistarelli, L., Melon, C., & Millan, M. J. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69062616.x · Cited by 99 · see citing works
Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure
D, M. F. M., Dünner, D. L., Greist, J. H., Preskorn, S., Trivedi, M. H., Zajecka, J., & Cohen, M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0603 · Cited by 94 · see citing works
Somatic Symptoms, Depression, and Antidepressant Treatment
Fava, M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0406 · Cited by 90 · see citing works
Electrophysiologic Evidence for Desensitization of α2-Adrenoceptors on Serotonin Terminals Following Long-Term Treatment with Drugs Increasing Norepinephrine Synaptic Concentration
Mongeau, R., de Montigny, C., & Blier, P. U. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.6 · Cited by 88 · see citing works
Simultaneous Increases of Extracellular Monoamines in Microdialysates from Hypothalamus of Conscious Rats by Duloxetine, a Dual Serotonin and Norepinephrine Uptake Inhibitor
Engleman, E. A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00093-f · Cited by 72 · see citing works
Effect of age on the pharmacokinetics of duloxetine in women
Skinner, M., Kuan, H., Skerjanec, A., Seger, M. E., Heathman, M. A., O’Brien, L. M., Reddy, S. R., & Knadler, M. P. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01963.x · Cited by 70 · see citing works
Buspirone Enhances Duloxetine‐ and Fluoxetine‐Induced Increases in Dialysate Levels of Dopamine and Noradrenaline, but Not Serotonin, in the Frontal Cortex of Freely Moving Rats
Gobert, A., Rivet, J., Cistarelli, L., & Millan, M. J. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68031326.x · Cited by 68 · see citing works
The Psychopharmacology of Painful Physical Symptoms in Depression
Stahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0501 · Cited by 60 · see citing works
Efficacy of Venlafaxine and Predictors of Response in a Prospective Open-Label Study of Patients With Treatment-Resistant Major Depression
Mitchell, P. B., Schweitzer, I., Burrows, G. D., Johnson, G., & Polonowita, A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00014 · Cited by 49 · see citing works
An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder
Berk, M., du Plessis, A. D., Birkett, M. A., & Richardt, D. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199705000-00003 · Cited by 47 · see citing works
Synthesis and biological activity of some known and putative duloxetine metabolites
Kuo, F., Gillespie, T. A., Kulanthaivel, P., Lantz, R. J., Ma, T., Nelson, D. L., Threlkeld, P. G., Wheeler, W. J., Yi, P., & Zmijewski, M. J. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.04.066 · Cited by 43 · see citing works
Unmet need: what justifies the search for a new antidepressant?
Greden, J. F. (2002) · PubMed · Cited by 41 · see citing works
WAY 100,635 enhances both the `antidepressant' actions of duloxetine and its influence on dialysate levels of serotonin in frontal cortex
Millan, M. J., Brocco, M., Veiga, S., Cistarelli, L., Melon, C., & Gobert, A. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01445-3 · Cited by 39 · see citing works
Sustained Response to Open-Label Venlafaxine in Drug-Resistant Major Depression
Schweitzer, I., Burrows, G., Tuckwell, V., Polonowita, A., Flynn, P., George, T. P., Theodoros, M. T., & Mitchell, P. B. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00010 · Cited by 34 · see citing works
Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus
Smith, J. E., & Lakoski, J. M. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)00024-1 · Cited by 22 · see citing works
The Tyramine Pressor Test May Have Limited Sensitivity, Especially in the Presence of Dual Serotonin/Norepinephrine Uptake Inhibition
Chalon, S. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00409-2 · Cited by 14 · see citing works

Flagged first, then by citations

Sorted by citations

Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor
Deecher, D. C., Beyer, C. E., Johnston, G. H., Bray, J. A., Shah, S., Abou-Gharbia, M. A., & Andree, T. H. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.103382 · Cited by 382 · see citing works
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Chonnam Medical Journal · doi:10.4068/cmj.2018.54.2.101 · Cited by 299 · see citing works
Neurotransmitter transporters and their impact on the development of psychopharmacology
Iversen, L. L. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706428 · Cited by 243 · see citing works
Natural Products Inhibitors of Monoamine Oxidases—Potential New Drug Leads for Neuroprotection, Neurological Disorders, and Neuroblastoma
Chaurasiya, N. D., León, F., Muhammad, I., & Tekwani, B. L. (2022) · Molecules · doi:10.3390/molecules27134297 · Cited by 82 · see citing works
Rational multidrug therapy in the treatment of neuropathic pain
Bačkonja, M.-M., Irving, G. A., & Argoff, C. (2006) · Current Pain and Headache Reports · doi:10.1007/s11916-006-0007-1 · Cited by 79 · see citing works
Spectroscopic (FT-IR, FT-Raman), quantum mechanical and docking studies on methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine
Kuruvilla, T. K., Muthu, S., Prasana, J. C., George, J., & Sevvanthi, S. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.07.097 · Cited by 78 · see citing works
Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1 Premutation
Tassone, F., Protic, D. D., Allen, E. G., Archibald, A. D., Baud, A., Brown, T. W., Budimirovic, D. B., Cohen, J., Dufour, B. D., Eiges, R., et al. (2023) · Cells · doi:10.3390/cells12182330 · Cited by 76 · see citing works
Depression, pain, and somatoform disorders
Henningsen, P., & Löwe, B. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000189880.11059.8d · Cited by 65 · see citing works
Neuropathic pain: Etiology, pathophysiology, mechanisms, and evaluations
Jay, G. W., & Barkin, R. L. (2014) · Disease-a-Month · doi:10.1016/j.disamonth.2013.12.001 · Cited by 63 · see citing works
Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial
Ramos, M. G., Hara, C., & Rocha, F. L. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000066 · Cited by 38 · see citing works
Dual acting norepinephrine reuptake inhibitors and 5-HT2A receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles
Heffernan, G. D., Coghlan, R. D., Manas, E. S., McDevitt, R. E., Li, Y., Mahaney, P. E., Robichaud, A. J., Huselton, C. A., Alfinito, P. D., Bray, J. A., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.09.023 · Cited by 35 · see citing works
Glutamatergic hypothesis of schizophrenia: involvement of Na+/K+-dependent glutamate transport
Nanitsos, E. K., Nguyen, K. T. D., Šťastný, F., & Balcar, V. J. (2005) · Journal of Biomedical Science · doi:10.1007/s11373-005-9015-0 · Cited by 32 · see citing works
Iridium-catalyzed enantioselective synthesis of chiral γ-amino alcohols and intermediates of (S)-duloxetine, (R)-fluoxetine, and (R)-atomoxetine
Liu, C., Zhang, L., Cao, L., Xiong, Y., Ma, Y., Cheng, R., & Ye, J. (2022) · Communications Chemistry · doi:10.1038/s42004-022-00678-4 · Cited by 27 · see citing works
Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression
Borsellino, P., Krider, R. I., Chea, D., Grinnell, R., & Vida, T. A. (2023) · Pharmaceuticals · doi:10.3390/ph16050742 · Cited by 29 · see citing works
5-Phenylthio-1,3-oxazinan-4-ones via hetero Diels–Alder reactions: synthesis of (R)- and (S)-Duloxetines and Fluoxetines
Panunzio, M., Tamanini, E., Bandini, E., Campana, E., D’Aurizio, A., & Vicennati, P. (2006) · Tetrahedron · doi:10.1016/j.tet.2006.10.006 · Cited by 24 · see citing works
Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression
Sindhu, P., Kumar, S., Iqbal, B., Ali, J., & Baboota, S. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.01.015 · Cited by 24 · see citing works
Fragile X Premutation: Medications, Therapy and Lifestyle Advice
Sodhi, D. K., & Hagerman, R. J. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s338846 · Cited by 22 · see citing works
The Dubious Effect of Milnacipran for the Treatment of Burning Mouth Syndrome
Sugimoto, K. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31822511c4 · Cited by 20 · see citing works
Effects of duloxetine on pain and walking distance in neuropathic pain models via modulation of the spinal monoamine system
Minami, K., Tamano, R., Kasai, E., Ōyama, H., Hasegawa, M., Shinohara, S., & Asaki, T. (2017) · European Journal of Pain · doi:10.1002/ejp.1125 · Cited by 20 · see citing works
Depression and Physical Illnesses: an Update
Mohit, M., Maruf, M., Ahmed, H., & Alam, M. T. (1970) · Bangladesh Medical Journal · doi:10.3329/bmj.v40i1.9966 · Cited by 16 · see citing works
Management of Chronic Pain Syndromes: Issues and Interventions
(2005) · Pain Medicine · doi:10.1111/j.1526-4637.2005.00054.x · Cited by 16 · see citing works
A selective α 2 B adrenoceptor agonist (A‐1262543) and duloxetine modulate nociceptive neurones in the medial prefrontal cortex, but not in the spinal cord of neuropathic rats
Chu, K. L., Xu, J., Frost, J., Li, L., Gomez, E. J., Dart, M. J., Jarvis, M. F., Meyer, M. D., & McGaraughty, S. (2014) · European Journal of Pain · doi:10.1002/ejp.586 · Cited by 15 · see citing works
Transferosome-Enhanced Transdermal Therapy: A Novel Approach for Duloxetine Delivery for Management of Neuropathic Pain
Salve, P. S., Qutub, M., Hussain, U., Tatode, A., & Tammewar, S. S. (2025) · BioNanoScience · doi:10.1007/s12668-025-01877-8 · Cited by 14 · see citing works
Polymer-based prolonged-release nanoformulation of duloxetine: fabrication, characterization and neuropharmacological assessments
Singh, G., Sarwal, A., Sharma, S., Prasad, P., Kuhad, A., & Ali, W. (2020) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2020.1851240 · Cited by 12 · see citing works
Molecular pathways linking the serotonin transporters (SERT) to depressive disorder: from mechanisms to treatments
Murthy, M. K. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.08.009 · Cited by 10 · see citing works
Synthesis of anti-depressant molecules via metal-catalyzed reactions: a review
Kanwal, A., Afzal, U., Zubair, M., Imran, M., & Rasool, N. (2024) · RSC Advances · doi:10.1039/d3ra06391g · Cited by 9 · see citing works
The Efficacy of Preoperative Duloxetine in Patients Undergoing Major Abdominal Cancer Surgery
Hetta, D. F., Elgalaly, N. A., & Mohammad, M. A. F. (2021) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000983 · Cited by 8 · see citing works
Treatment of Psychiatric Comorbidities in a Patient With Becker Muscular Dystrophy
Chaichana, K. L., Buffington, A. L. H., Brandes, M., Edwin, D. H., & Lee, H. B. (2007) · Psychosomatics · doi:10.1176/appi.psy.48.2.167 · Cited by 6 · see citing works
Suspected duloxetine-induced restless legs syndrome phenotypic variant: a case report
Shao, Y., Chen, Y., Wang, S., Li, C., Sun, H., & Sun, X. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05763-7 · Cited by 4 · see citing works
Pediatric Rehabilitation: 3. Facilitating Family‐Centered Treatment Decisions
Moberg‐Wolff, E. A., Kim, C. T., Murphy, N., Trovato, M. K., & Kim, H. (2010) · PM&R · doi:10.1016/j.pmrj.2009.12.003 · Cited by 3 · see citing works
Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial.
Wang, Z., Xu, X., Tan, Q., Li, K., Ma, C., Xie, S., Gao, C., Wang, G., & Li, H. (2015) · Europe PMC (PubMed Central) · doi:10.11919/j.issn.1002-0829.215064 · Cited by 3 · see citing works
Chiral P,N,N-Ligands for the Manganese-Catalyzed Asymmetric Formal Hydroamination of Allylic Alcohols
Li, Q., Song, X., Wu, Z., Li, L., Zhu, T., He, X., & Hou, C. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c01353 · Cited by 2 · see citing works
The neurobiology and treatment of late-life depression
Hegerl, U., Holtzheimer, P. E., Mergl, R., & McDonald, W. M. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00016-4 · Cited by 1 · see citing works
Duloxetine usage in depression
Hu, B. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00094-3 · Cited by 1 · see citing works
Pharmacology Update: New Influenza Vaccine and Prioritizing Parkinson’s Management
Luggen, A. S. (2005) · Geriatric Nursing · doi:10.1016/j.gerinurse.2005.09.004
A comparison of duloxetine hydrochloride with fluoxetine hydrochloride in major depressive disorders: a pilot study
Sah, R. K., Rehan, H. S., Unni, K. E. S., Chopra, D., Manak, S., & Narula, P. K. (2010) · Health · doi:10.4236/health.2010.26093
Research Review: A New Option in Pain Management—Duloxetine versus Placebo in Patients with Painful Diabetic Neuropathy
Resnick, B. M. (2005) · Geriatric Nursing · doi:10.1016/j.gerinurse.2005.09.017
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.638
D
(2007) · Elsevier eBooks · doi:10.1016/b978-141600208-6.50008-5
A Modular and Scalable Route to Protected Cyclopropane Amino Acid Building Blocks
Swan, C., Edmonds, A. G., Argent, S. P., & Mitchell, N. J. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c01341
Duloxetine ameliorates chronic stress-induced depressive behaviors by normalizing hippocampal SIK2-CRTC1 signaling
Xu, H., Fan, H., Jiang, B., Ding, E.-H., Hou, P., & Zhu, W.-B. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1836082
BindingDB Entry 3474: Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.
BindingDB (2009) · UC San Diego · doi:10.7270/q26q1vk2
BindingDB Entry 5521: Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor.
BindingDB (2012) · UC San Diego · doi:10.7270/q2sf2trs

Authors: Kirwin, J. L., & Gören, J. L.
Affiliations: Northeastern University (US)
McLean Hospital (US)
ORCID: Kirwin, Jennifer L.
Gören, Jessica L.
Venue: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Publisher: Wiley
Published: 2005-03
Volume: 25
Issue: 3
Pages: 396-410
ISSN: 0277-0008 (ISSN-L)
1875-9114
DOI: 10.1592/phco.25.3.396.61600
OpenAlex: W2080466203
Cited by: 42
References: 56
Citations by year: 2026: 1 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 1 · 2018: 3 · 2017: 1 · 2015: 1 · 2014: 2 · 2012: 1
FWCI: 2.55
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2512 d)
Locations: Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords: duloxetine, major depressive disorder, serotonin-norepinephrine reuptake inhibitors, antidepressants, treatment-resistant depression, antidepressant efficacy, antidepressant side effects, diabetic peripheral neuropathic pain, stress urinary incontinence, somatic symptoms of depression, cardiovascular side effects, sexual side effects
MeSH terms: Duloxetine Hydrochloride, Adolescent, Adult, Aged, Depressive Disorder, Major, Major Depressive Disorder, Drug Interactions, Humans, Middle Aged, Thiophenes, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Duloxetine: A Dual Serotonin‐Norepinephrine Reuptake Inhibitor for Treatment of Major Depressive Disorder

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks